Zhang Yinsheng
Chemical R&D, Pfizer Inc, Groton, CT, USA.
J Labelled Comp Radiopharm. 2017 Nov;60(13):608-615. doi: 10.1002/jlcr.3559. Epub 2017 Sep 21.
To make a detailed characterization of the mechanism of inhibition and selectivity of a novel fatty acid amide hydrolase inhibitor PF-622, 3 tritium isotopomers were prepared. [ H]PF-622a labeled at the piperazine ring B and [ H]PF-622b labeled at both the ring B and phenyl ring A were synthesized via catalytic H(hydrogen)-T(tritium) exchange, utilizing 1 equiv and excess of Crabtree's catalyst, respectively. The preparation of [ H]PF-622c labeled only at the phenyl ring A was achieved via tritiodebromination of the bromide precursor, using Pd(PPh ) as a catalyst. The observations from these tritiation reactions might open a new perspective in the labeling for the targets having a similar moiety.
为了详细表征新型脂肪酸酰胺水解酶抑制剂PF-622的抑制机制和选择性,制备了3种氚同位素异构体。通过催化氢(H)-氚(T)交换分别使用1当量和过量的克拉布特里催化剂合成了在哌嗪环B上标记的[³H]PF-622a和在环B和苯环A上均标记的[³H]PF-622b。仅在苯环A上标记的[³H]PF-622c是通过使用Pd(PPh₃)₄作为催化剂对溴化物前体进行氚代脱溴反应制备的。这些氚化反应的观察结果可能为具有相似部分的靶标的标记开辟新的视角。